Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease

Inclusion Criteria

• •1. Subjects voluntarily sign informed consent by themselves or their legal guardians and complete the study procedures, follow-up examination and treatment.
• •2. At the time of screening, subjects should be aged from 12 to 35 years old, regardless of gender.
• •3. History of at least 100 mL/kilograms (kg)/year of packed red blood cells (pRBC) transfusions in the prior 2 years before screening.
• •4. Subjects diagnosed with Hemoglobin H-Constant Spring disease (--/ααCS) with HBA2 c.427T\>C mutation.